Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology
Asunercept Plus Radiotherapy Significantly Prolongs Time to Deterioration of Quality of Life Compared to Radiotherapy Alone in Patients with Recurrent Glioblastoma
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that a new publication in Journal of Neuro-Oncology1 shows that in patients with recurrent glioblastoma, treatment with asunercept in combination with radiotherapy is associated with a statistically significant prolongation in time to deterioration of quality of life beyond progression of the disease compared to treatment with radiotherapy alone.